For example, in two studies of patients with metastatic renal cell carcinoma receiving anti-VEGF or mTOR-inhibitors and lung cancer receiving EGFR-TKI therapy, patients treated with statins concurrently had improved overall survival compared to statin non-users (149, 150). This evidence concerns the gene MTOR and lung cancer.